Asthma Patents (Class 514/826)
-
Patent number: 6702997Abstract: The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.Type: GrantFiled: December 28, 2001Date of Patent: March 9, 2004Assignee: Dey, L.P.Inventors: Imtiaz Chaudry, Partha Banerjee
-
Patent number: 6699459Abstract: The present invention relates to a method of treating lung inflammation in a subject which includes administering butylated hydroxyanisol to the subject in an amount effective to treat lung inflammation. The invention also relates to methods of inhibiting interferon regulatory factor activation in a subject and in an alveolar cell. Another aspect of the invention relates to an assay.Type: GrantFiled: March 1, 2002Date of Patent: March 2, 2004Assignee: The Board of Regents of the University of Texas SystemInventors: Antonella Casola, Roberto Garofalo, Allan R. Brasier
-
Patent number: 6689810Abstract: The present invention pertains to a method for treating a pulmonary disease state in mammals by altering indigenous in vivo levels of nitric oxide in mammalian cells. The method comprises contacting the mammalian cells with a therapeutically effective amount of a nitric oxide mediator selected from the group consisting of pyruvates, pyruvate precursors, &agr;-keto acids having four or more carbon atoms, precursors of &agr;-keto acids having four or more carbon atoms, and the salts thereof. The method may further comprise contacting the mammalian cells with a therapeutic agent and a nitric oxide source selected from the group consisting of nitric oxide, nitric oxide precursors, and nitric oxide stimulators.Type: GrantFiled: July 25, 2002Date of Patent: February 10, 2004Assignee: Cellular Sciences, Inc.Inventor: Alain Martin
-
Patent number: 6689748Abstract: The invention provides a method for preventing and treating the harmful biological effects of biochemicals secreted from activated mast cells in the organism of warm blooded animals and more especially human beings, said effects being associated with allergy (including but not limited to allergic conjunctivitis, allergic rhinitis, allergic otitis, asthma, allergic uticaria, food allergy and atopic dermatitis), hyperproliferative diseases such as leukemia and systemic mastocytosis, interstitial cystitis, inflammatory bowel disease, irritable bowel syndrome, osteoporosis and scleroderma. The method consists in administering to said animals and especially to human beings an effective amount of a proteoglycan such as chondroitin sulfate with mast cell secretion inhibitory activity, alone or in combination with one or more synergistic adjuvants such those belonging to the class of flavonoids or compounds with histamine-1 receptor antagonist activity.Type: GrantFiled: April 8, 1998Date of Patent: February 10, 2004Inventor: Theoharis C. Theoharides
-
Patent number: 6685932Abstract: The design of antagonists of 4-helix bundle cytokine specific receptors, mimetic peptides that are able to act as such antagonists and their use as pharmaceutical agents is disclosed.Type: GrantFiled: May 12, 2000Date of Patent: February 3, 2004Assignee: Europaisches Laboratorium MolekularbiologieInventors: Helena Domingues, David Cregut, Walter Sebald, Hartmut Oschkinat, Luis Serrano
-
Patent number: 6677322Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: January 16, 2002Date of Patent: January 13, 2004Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6677323Abstract: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.Type: GrantFiled: January 16, 2002Date of Patent: January 13, 2004Assignee: Schering CorporationInventors: Joel A. Sequeira, Francis M. Cuss, Keith B. Nolop, Imtiaz A. Chaudry, Nagamani Nagabhushan, James E. Patrick, Mitchell Cayen
-
Patent number: 6670394Abstract: This invention relates to a method for the prophylaxis of or for treating COPD by administering a PDE4 inhibitor which has a defined therapeutic ratio.Type: GrantFiled: August 31, 2001Date of Patent: December 30, 2003Assignee: SmithKline Beecham CorporationInventors: Siegfried B. Christensen, IV, Mary S. Barnette, Theodore J. Torphy
-
Patent number: 6664227Abstract: Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.Type: GrantFiled: November 29, 1999Date of Patent: December 16, 2003Assignees: Genetics Institute, LLC, The United States of America as represented by the Department of Health and Human ServicesInventors: Thomas A. Wynn, Monica G. Chiaramonte, Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew J. Whitters, Clive Wood
-
Patent number: 6645486Abstract: The methods of this invention relate to immunizing animals with conjugates of cytokines and a carrier to induce a prolonged high titre antibody response specific for the cytokine. This invention also relates to the treatment of pathological conditions, e.g., eosinophilia and allograft rejection, associated with the production of cytokines, in particular interleukins, e.g., IL-4, IL-5, IL-9, and IL-13, by immunization with the cytokine conjugates or by administration of antibodies specific for the cytokine. This invention also relates to compositions comprising the cytokine conjugates and the conjugates per se.Type: GrantFiled: January 25, 2000Date of Patent: November 11, 2003Assignee: Ludwig Institute for Cancer ResearchInventors: Jacques Van Snick, Jean Christophe Renauld, Mélisande Richard
-
Patent number: 6645492Abstract: A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual.Type: GrantFiled: May 4, 2001Date of Patent: November 11, 2003Assignee: Genaera CorporationInventors: Roy Clifford Levitt, W. Lee Maloy, U. Prasad Kari, Nicholas C. Nicolaides
-
Publication number: 20030195141Abstract: Methods for inhibiting an inflammatory reaction in a mammal and pharmaceutical compositions are provided.Type: ApplicationFiled: February 4, 2003Publication date: October 16, 2003Inventor: Ronald Mathison
-
Publication number: 20030190303Abstract: The present invention relates to pharmaceutical compositions and methods for treating allergic disorders characterized by a local immune response including inflammatory skin reactions, asthma, and arthritis.Type: ApplicationFiled: April 10, 1998Publication date: October 9, 2003Inventors: IAN KIMBER, MARIE CUMBERBATCH, REBECCA J. DEARMAN, ORLA M. CONNEELY, PAULINE WARD
-
Patent number: 6630176Abstract: The present invention provides herbal compositions that can prevent or reduce the severity, intensity, or duration of allergic and/or asthmatic symptoms and/or can prevent or delay the development of an allergic or asthmatic response to an antigen. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutical carriers or excipients, and may be administered prior to, during, or after the development of allergic or asthmatic symptoms in sensitized individuals. Alternatively or additionally, the compositions may be administered prior to sensitization to a particular antigen; preferably substantially concurrently with exposure to the antigen.Type: GrantFiled: March 7, 2001Date of Patent: October 7, 2003Assignee: Mount Sinai School of Medicine of New York UniversityInventors: Xiu-Min Li, Hugh A. Sampson
-
Patent number: 6630466Abstract: The present invention relates to new medicament compositions based on anticholinergic compounds, which have a long-lasting effect, and salmeterol, processes for their production and their use in the therapy of respiratory ailments.Type: GrantFiled: February 14, 2002Date of Patent: October 7, 2003Assignee: Boehringer Ingelheim Pharma KGInventors: Karl-Heinz Bozung, Michel Pairet, Richard Reichl, Alexander Walland
-
Patent number: 6623723Abstract: The present invention is directed to a method for treating bronchial constriction in mammals. The method comprises contacting mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to produce bronchial dilation. The present invention is also directed to a method for treating airway disease in mammals. The method comprises contacting mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in an amount from about 0.0001 millimoles to about 0.005 millimoles. The present invention is further directed to a method for treating airway disease in mammals. The method comprises contacting the mammalian lung with a compound selected from the group consisting of pyruvate and pyruvate precursors. The compound is present in a therapeutically effective amount to prevent bronchial spasm.Type: GrantFiled: August 21, 2001Date of Patent: September 23, 2003Assignee: Cellular Sciences Inc.Inventor: Stanley E. Katz
-
Patent number: 6617355Abstract: Asthma is ameliorated, and mild or moderate asthma is prevented from progressing to more severe asthma by administering agents which prevent and/or accommodate for S-nitrosothiol breakdown.Type: GrantFiled: November 4, 1999Date of Patent: September 9, 2003Assignees: The University of Virginia Patent Foundation, Duke University, The Medical College of Wisconsin Research Foundation, Inc.Inventors: Benjamin Gaston, Jonathan S. Stamler, Owen W. Griffith
-
Patent number: 6608054Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and endothelin antagonists, processes for preparing them and their use in the treatment of respiratory tract diseases.Type: GrantFiled: March 18, 2002Date of Patent: August 19, 2003Assignee: Boehringer Ingelheim Pharma KGInventors: Christopher J. M. Meade, Michel Pairet, Michael P. Pieper
-
Patent number: 6605641Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z), 14(Z)-dienoic acid and 20-, 21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z), 8(Z), 11(Z), 14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z), 15(Z)-dienoic acid.Type: GrantFiled: December 14, 2001Date of Patent: August 12, 2003Assignee: MCW Research FoundationInventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
-
Patent number: 6602850Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: June 16, 2000Date of Patent: August 5, 2003Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 6599914Abstract: Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.Type: GrantFiled: April 24, 2001Date of Patent: July 29, 2003Assignee: Schering CorporationInventors: Robert P. Schleimer, John Schroeder, William Kreutner
-
Patent number: 6596687Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.Type: GrantFiled: January 13, 2000Date of Patent: July 22, 2003Assignee: Biogen, Inc.Inventors: Ko-Chung Lin, Steven P. Adams, Alfredo C. Castro, Craig N. Zimmerman, Julio Hernan Cuervo, Wen-Cherng Lee, Charles E. Hammond, Mary Beth Carter, Ronald G. Almquist
-
Patent number: 6596769Abstract: 20-HETE agonists and antagonists are disclosed along with therapeutic applications. In a preferable form of the invention, the 20-HETE agonists are selected from the group consisting of 21-hydroxyheneicosa-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid, 20-hydroxyeicosa-5(Z),4(Z)-dienoic acid and 20-,21-dimethyl 20-HETE. Preferable 20-HETE antagonists include 5(S)-HETE, 15(S)-HETE, 19(S)-HETE, 19-hydroxynonadeca-5(Z),8(Z),11(Z),14(Z)-tetraenoic acid and 20-hydroxyeicosa 6(Z),15(Z)-dienoic acid.Type: GrantFiled: December 14, 2001Date of Patent: July 22, 2003Assignee: MCW Research FoundationInventors: Richard J. Roman, John R. Falck, Magdalena Alonso-Galicia, Elizabeth R. Jacobs, David R. Harder
-
Patent number: 6593359Abstract: The use of at least one &ggr;-RAR receptor-specific agonist ligand to prepare a pharmaceutical composition for increasing the rate of apoptosis in at least one cell population in which apoptosis may be induced by activating &ggr;-RAR receptors is disclosed. The composition is particularly useful for treating a disease or disorder related to an insufficient rate of apoptosis in at least one cell population in which apoptosis may be induced by activating &ggr;-RAR receptors. The use of at least one &ggr;-RAR receptor-specific agonist ligand as the apoptosis inducer in a cosmetic composition is also disclosed. Said composition may be used to prevent and/or control photo-ageing or chronological ageing of the skin.Type: GrantFiled: July 15, 1998Date of Patent: July 15, 2003Assignee: Centre International de Recherches Dermatologioues Galderma (C.I.R.D. Galderma)Inventors: Laszlo Fesus, Zsuzsa Szondy, Uwe Reichert
-
Patent number: 6589508Abstract: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.Type: GrantFiled: August 9, 2001Date of Patent: July 8, 2003Assignee: Sepracor Inc.Inventors: Gunnar Aberg, John Morley
-
Patent number: 6569436Abstract: This invention is directed to methods of preventing or reducing the severity of asthma or the risk of development of same in an individual. The method relies on administration to the airways of the individual of an immunologically effective dose of a mycobacterium based vaccine. The mycobacteria are effective in inducing a Thl type immune response in the individual.Type: GrantFiled: October 5, 1998Date of Patent: May 27, 2003Assignee: The Malaghan Institute of Medical ResearchInventors: Graham Stephen Le Gros, Charles Richard William Beasley, John William Holloway, Klaus Erb
-
Patent number: 6555105Abstract: Modifications to RANTES can result in the modified polypeptide acting as a RANTES or MIP-1&agr; antagonist. Such antagonists can be used in therapy to reduce inflammation. They are also useful in studying the properties of RANTES or of MIP-1&agr;.Type: GrantFiled: August 17, 2000Date of Patent: April 29, 2003Assignee: Glaxo Group LimitedInventors: Amanda E. I. Proudfoot, Timothy N. C. Wells
-
Patent number: 6555576Abstract: Methods of treating exercise-induced asthma using a PDE-4 inhibitor are disclosed.Type: GrantFiled: August 31, 2001Date of Patent: April 29, 2003Assignee: SmithKline Beecham CorporationInventors: Richard Nieman, Theodore J. Torphy, Siegfried B. Christensen, IV
-
Patent number: 6548540Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.Type: GrantFiled: December 12, 2000Date of Patent: April 15, 2003Assignee: Charlotte-Mecklenburg Hospital AuthorityInventor: Thomas Preston Kennedy
-
Patent number: 6548500Abstract: Conformationally constrained compounds which mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetics have utility in the treatment of cell adhesion-indicated diseases, such as multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease.Type: GrantFiled: December 19, 2000Date of Patent: April 15, 2003Assignee: Molecumetics Ltd.Inventors: Michael Kahn, Masakatsu Eguchi, Hwa-Ok Kim, Marcin Stasiak
-
Patent number: 6537524Abstract: A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) a tiotropium salt of a pharmaceutically acceptable acid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease.Type: GrantFiled: August 8, 2001Date of Patent: March 25, 2003Assignee: Novartis AGInventors: Ian Francis Hassan, Jeremy Guy Clarke, Bernard Cuenoud
-
Patent number: 6538002Abstract: The present in to s directed to compounds of the formula I: (wherein R1, R2, R3, R7, R8, X, Y, Z, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3.Type: GrantFiled: June 8, 2000Date of Patent: March 25, 2003Assignee: Merck & Co., Inc.Inventors: Paul E. Finke, Malcolm Maccoss, Sander G. Mills, Bryan Oates
-
Patent number: 6534486Abstract: A series of 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives with broad anti-inflammatory properties which inhibit leukocyte recruitment and activation and which are agonists of the adenosine 2a receptor are described.Type: GrantFiled: February 28, 2001Date of Patent: March 18, 2003Assignee: SmithKline Beecham CorporationInventors: David George Allen, Chuen Chan, Caroline Mary Cook, Richard Peter Charles Cousins, Brian Cox, Hazel Joan Dyke, Frank Ellis, Joanna Victoria Geden, Heather Hobbs, Suzanne Elaine Keeling, Alison Judith Redgrave, Stephen Swanson, Caroline Whitworth, David Bays
-
Patent number: 6528494Abstract: There are provided according to the invention novel compounds of formula I wherein R1, R2 and R3 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.Type: GrantFiled: December 19, 2001Date of Patent: March 4, 2003Inventors: Brian Cox, Suzanne Elaine Keeling, David George Allen, Alison Judith Redgrave, Michael David Barker, Heather Hobbs, Thomas Davis Roper, IV, Joanna Victoria Geden
-
Patent number: 6518274Abstract: The invention relates to the use of cycloventabenzofuran derivatives for the production of a medicament for the treatment of nuclear factor of &kgr;B-dependent diseases.Type: GrantFiled: April 18, 2001Date of Patent: February 11, 2003Assignee: Bayer AktiengesellschaftInventors: Matthias Gehling, Jörg Baumgarten, Axel Kretschmer, Horst-Peter Antonicek, Peter Proksch, Bambang Wahyu Nugroho, Frank Bohnenstengel
-
Patent number: 6506796Abstract: Methods of cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of 6-3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthanoic acid.Type: GrantFiled: July 25, 2000Date of Patent: January 14, 2003Assignee: Centre International de Recherches Dermatologiques GaldermaInventors: Laszlo Fesus, Zsuzsa Szondy, Uwe Reichert
-
Patent number: 6506377Abstract: A method for enhancing the expression of aquaporin proteins by contacting aquaporin producing cells with interferon-&agr; is described. The method enables treatment of patients afflicted with disease states characterized by xerosis.Type: GrantFiled: September 27, 2001Date of Patent: January 14, 2003Assignees: Amarillo Biosciences, Inc., East Tennessee State UniversityInventors: Joseph M. Cummins, J. Kelly Smith
-
Patent number: 6506802Abstract: Novel disulfide derivatives useful for preventing or treating allergic diseases of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis are disclosed. The disulfide derivatives act as mast cell stabilizers.Type: GrantFiled: May 22, 2002Date of Patent: January 14, 2003Assignee: Alcon Universal Ltd.Inventors: Zixia Feng, Mark R. Hellberg, Steven T. Miller
-
Patent number: 6503953Abstract: A method for treating an atopic disorder in a patient is provided. The method comprises administering to the patient an effective amount of at least one of an antifungal and an antibiotic over a period of time. The method further comprises reducing over the period of time the application of emollients to the patient by at least about 50%, relative to the amount of application of emollients prior to treatment.Type: GrantFiled: July 26, 2001Date of Patent: January 7, 2003Assignee: Atopic Pty Ltd.Inventor: John K. Vyden
-
Patent number: 6497877Abstract: Plasminogen activator acts as an anti-inflammatory agent by inhibiting generation of superoxide anion by a mechanism that is not related to L-arginine, is not dependent on thrombolytic activity, and is not a function of oxygen free radical scavenging. Moreover, in in vivo models of inflammation, treatment with plasminogen activator reduces edema without inhibiting neutrophil infiltration in in vivo models of inflammation.Type: GrantFiled: October 22, 1999Date of Patent: December 24, 2002Assignee: University Technology CorporationInventors: Kathleen A. Stringer, Brooks M. Hybertson, John E. Repine, Joe M. McCord
-
Patent number: 6495592Abstract: The present invention offers a tracheal smooth muscle relaxant containing the compound represented by the following formula (1) or pharmacologically acceptable salt thereof as an effective ingredient.Type: GrantFiled: June 30, 2000Date of Patent: December 17, 2002Assignee: Nippon Suisan Kaisha, Ltd.Inventors: Shinya Yamashita, Jiro Takeo, Shuji Jinno, Yasuyo Kogure, Hiroyuki Onuki, Takaaki Okita, Junichiro Hata, Yasuhiro Fukuda, Naomi Ohtsuka
-
Patent number: 6482391Abstract: A method and apparatus is disclosed for treating asthma and other respiratory conditions. A medicament comprising a surface active phospholipid (SAPL) is prepared in the form of a fine powder and administered to the lungs in a gas stream. A preferred SAPL is a solid blend of dipalmitoyl phosphatidyl choline (DPPC) and phosphatidyl glycerol (PG).Type: GrantFiled: August 10, 2000Date of Patent: November 19, 2002Assignee: Britannia Pharmaceuticals LimitedInventors: Brain Andrew Hills, Derek Alan Woodcock
-
Patent number: 6482856Abstract: A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.Type: GrantFiled: July 7, 1999Date of Patent: November 19, 2002Assignee: Cellular Sciences, Inc.Inventor: Stanley E. Katz
-
Patent number: 6479035Abstract: There is provided according to the invention a pharmaceutical aerosol formulation which comprises: (i) fluticasone propionate and (ii) a hydrofluoroalkane (HFA) propellant, characterised in that the fluticasone propionate is completely dissolved in the formulation. The invention also provided canisters containing the formulation and uses thereof.Type: GrantFiled: September 11, 2000Date of Patent: November 12, 2002Assignee: SmithKline Beecham CorporationInventors: Alan Leslie Cripps, Paul Johnson
-
Patent number: 6458837Abstract: The invention discloses stable diesters of chelating agents of divalent metal ions, processes for their preparation and pharmaceutical compositions thereof. Most preferred compounds according to the present invention are stable lipophilic diesters comprising a covalent conjugate of a BAPTA and a pharmaceutically acceptable alcohol. The diesters are useful in a method for treating a condition or disease related to an excess of divalent metal ions, and in particular for the treatment of a condition or disease related to elevated levels of intracellular calcium ions, such as in brain or cardiac ischemia, stroke, epilepsy, Alzheimer's disease or cardiac arrhythmia and in open heart surgery.Type: GrantFiled: March 27, 2000Date of Patent: October 1, 2002Assignee: D-Pharm Ltd.Inventors: Alexander Kozak, Israel Shapiro
-
Patent number: 6455524Abstract: The present invention relates to new medicament compositions based on anticholinergic compounds, which have a long-lasting effect, and &bgr;-mimetics, which have a long-lasting effect, processes for their production and their use in the therapy of respiratory ailments.Type: GrantFiled: May 9, 2000Date of Patent: September 24, 2002Assignee: Boehringer Ingelheim Pharma KGInventors: Karl-Heinz Bozung, Michel Pairet, Richard Reichl, Alexander Walland
-
Patent number: 6451354Abstract: A salt-spice-herbal composition known as Amrita Bindu that is clinically useful for reducing IgE production and treating secondary allergic responses is disclosed.Type: GrantFiled: October 25, 2000Date of Patent: September 17, 2002Assignee: Pharma Terra, Inc.Inventors: Rolland Hebert, Edayatimangalam Raja Bhavani Shanmugasundaram, Kalathkal Radha Shanmugasundaram
-
Patent number: 6451352Abstract: The invention concerns the use of iso-osmotic saline solutions in particular obtained from sea water, to obtain a medicine designed for a treatment preventing and limiting the release of chemical mediators responsible for causing inflammatory phenomena in the human respiratory tracts.Type: GrantFiled: May 24, 2001Date of Patent: September 17, 2002Assignee: Laboratoires Goemar S.A.Inventors: Jean-Claude Yvin, Olivier Tabary, Jacky Jacquot, Edith Puchelle
-
Patent number: 6451288Abstract: Compounds of Formula I: wherein: X1, and X2 are each independently either O− or S−; X3 and X4 are each independently either —H or —OH, with the proviso that X3 and X4 are not simultaneously —H; R1 is selected from the group consisting of O, imido, methylene and dihalomethylene; R2 is selected from the group consisting of H, halo, alkyl, substituted alkyl, alkoxyl, nitro and azido; R3 is selected from the group consisting of H, alkyl, acyl, aryl, and arylalkyl; and R4 is selected from the group consisting of —OR′, —SR′, —NR′, and —NR′R″, wherein R′ and R″ are independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, alkoxyl, and aryloxyl, with the proviso that R′ is absent when R4 is double bonded from an oxygen or sulfur atom to the carbon at the 4-position of the pyrimidine ring, are used in methods of hydrating lung mucus secrType: GrantFiled: August 24, 2000Date of Patent: September 17, 2002Assignees: The University of North Carolina at Chapel Hill, Inspire Pharmaceuticals, Inc.Inventors: Richard C. Boucher, Jr., Sammy Ray Shaver, William Pendergast, Benjamin Yerxa, Janet L. Rideout, Robert Dougherty, Dallas Croom
-
Patent number: 6436443Abstract: Improved porous particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the porous particles are made of a biodegradable material and have a mass density less than 0.4 g/cm3/. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear &agr;-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, porous particles having a relatively large mean diameter, for example greater than 5 &mgr;m, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung.Type: GrantFiled: June 25, 2001Date of Patent: August 20, 2002Assignees: The Penn Research Foundation, Inc., Massachesetts Institute of TechnologyInventors: David A. Edwards, Giovanni Caponetti, Jeffrey S. Hrkach, Noah Lotan, Justin Hanes, Robert S. Langer, Abdellaziz Ben-Jebria